Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.14 -5.00% -0.06
ALNA closed down 5.0 percent on Thursday, April 15, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ALNA trend table...

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -5.00%
Wide Bands Range Expansion -5.00%
Oversold Stochastic Weakness -5.00%
Hammer Candlestick Bullish -8.80%
Lizard Bullish Bullish Day Trade Setup -8.80%
Pocket Pivot Bullish Swing Setup -8.80%
Older End-of-Day Signals for ALNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Lower Bollinger Band about 17 hours ago
Lower Bollinger Band Support about 17 hours ago
Down 1 ATR about 17 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Allena Pharmaceuticals, Inc. Description

Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Gastrointestinal Kidney Diseases Orphan Disease Orphan Diseases Crystals Hyperoxaluria

Is ALNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.39
52 Week Low 1.07
Average Volume 1,198,150
200-Day Moving Average 1.48
50-Day Moving Average 1.63
20-Day Moving Average 1.38
10-Day Moving Average 1.28
Average True Range 0.11
ADX 31.61
+DI 10.51
-DI 34.67
Chandelier Exit (Long, 3 ATRs ) 1.40
Chandelier Exit (Short, 3 ATRs ) 1.42
Upper Bollinger Band 1.67
Lower Bollinger Band 1.10
Percent B (%b) 0.06
BandWidth 40.52
MACD Line -0.11
MACD Signal Line -0.10
MACD Histogram -0.0142
Fundamentals Value
Market Cap 43.65 Million
Num Shares 38.3 Million
EPS -2.01
Price-to-Earnings (P/E) Ratio -0.57
Price-to-Sales 0.00
Price-to-Book 3.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.38
Resistance 3 (R3) 1.39 1.32 1.34
Resistance 2 (R2) 1.32 1.26 1.32 1.33
Resistance 1 (R1) 1.23 1.22 1.20 1.22 1.31
Pivot Point 1.16 1.16 1.14 1.16 1.16
Support 1 (S1) 1.07 1.10 1.04 1.06 0.97
Support 2 (S2) 1.00 1.06 1.00 0.95
Support 3 (S3) 0.91 1.00 0.94
Support 4 (S4) 0.90